Fig. 2From: Hippocampal CA1 βCaMKII mediates neuroinflammatory responses via COX-2/PGE2 signaling pathways in depressionCelecoxib ameliorated depression-like behaviors in a rat model of depression. a Treatment of celecoxib (20 mg/kg) or fluoxetine (40 mg/kg) reversed the decreases in percent of sucrose consumption of CUMS rats. b Treatment of celecoxib (40 mg/kg) reversed the increases in immobility times and decreases in swimming times of CUMS rats in the forced swim test. c Treatment of celecoxib (40 mg/kg) reversed the decreases in percentage of sucrose consumption of rats subjected to LPS-induced depression. d Treatment of celecoxib (40 mg/kg) reversed the increases in immobility times and decreases in swimming times of rats subjected to LPS-induced depression. All values are presented as means ± SEM (N = 18). *P < 0.05, **P < 0.01, ***P < 0.001 CUMS (or LPS) vs control group; #P < 0.05, ##P < 0.01, ###P < 0.001 CUMS (or LPS)+Cele vs depression group; &P < 0.05, &&P < 0.01, &&&P < 0.001 CUMS (or LPS)+FLX vs depression group (Cele, celecoxib; FLX, fluoxetine)Back to article page